Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc. Chief Financial Officer Max Rosett reported an exercise-and-sale transaction in company stock. He exercised stock options covering 60,000 shares of common stock at an exercise price of $1.05 per share and, on the same date, sold 60,000 shares of common stock in open-market transactions.
The weighted average sale price was $18.23 per share, with individual trade prices ranging from $17.95 to $18.66. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following the transactions, Rosett directly holds 54,037 shares of Immunome common stock, and the exercised option is now fully vested and fully exercised.
IMNM reported a proposed sale of 60,000 shares of common stock by means of a stock option exercise to occur on 06/15/2026 for cash. The filing notes a prior sale by Max Rosett of 65,000 shares on 04/02/2026 for $1,425,084.64.
The filing lists transaction mechanics as an issuer-related stock option exercise and records broker information for Fidelity Brokerage Services LLC. It is a routine Section 144 resale notice reporting planned insider-related dispositions.
Immunome Inc. director Sandra M. Swain received a grant of stock options covering 9,897 shares of common stock. The options have an exercise price of $18.16 per share and expire on June 9, 2036.
The award vests in four equal quarterly installments starting on June 10, 2026, with additional vesting on the same day of each succeeding fiscal quarter until the one-year anniversary, as long as she continues serving with the company on each vesting date. Following this grant, she holds options for 9,897 shares directly.
Immunome Inc. director Philip Wagenheim received a grant of 9,897 director stock options, each giving the right to buy common stock at an exercise price of $18.16 per share. These options expire on June 9, 2036 and are reported as directly owned.
The option vests in four equal quarterly installments starting on June 10, 2026, with additional vesting dates on the same day of each succeeding fiscal quarter over the following year, conditioned on his continued service with the company at each vesting date.
Immunome Inc. director Jean Jacques Bienaimé received a new stock option grant covering 9,897 shares of common stock. The option has an exercise price of $18.16 per share and expires on June 9, 2036. Following this grant, he holds options for 9,897 shares directly.
The option vests in four equal quarterly installments, beginning on June 10, 2026 and continuing on the same day of each succeeding fiscal quarter for one year, subject to his continued service with the company on each vesting date.
Immunome Inc. reported a Form 4 insider transaction involving stock options linked to director James P. Boylan’s board service. A director stock option covering 9,897 shares of common stock was granted with an exercise price of $18.16 per share and an expiration date of June 9, 2036.
Mr. Boylan has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title, and interest in them. The option vests in four equal quarterly installments starting on June 10, 2026, conditioned on his continuous service with the company on each vesting date, and results in a total of 9,897 derivative securities held after the award.
Immunome Inc. director-related entity receives new stock option grant. A director stock option covering 9,897 shares of Immunome common stock was granted at an exercise price of $18.16 per share, expiring on June 9, 2036. The filing lists director Isaac Barchas as reporting person, but he has agreed that any securities granted for his board service are held for the benefit of Arsenal Bridge Ventures, and he disclaims beneficial ownership and all rights in the reported securities.
The option vests in four equal quarterly installments starting on June 10, 2026, through the one-year anniversary, with each vesting date tied to continued service with Immunome. After this award, the reported derivative position in these options is 9,897 units.
Immunome Inc. director Carol Schafer received a grant of stock options as part of her compensation. She was awarded options covering 9,897 shares of common stock at an exercise price of $18.16 per share, expiring on June 9, 2036.
The options vest in four equal quarterly installments starting on June 10, 2026, continuing on the same day of each succeeding fiscal quarter for one year, as long as she remains in continuous service with the company. Following this grant, she directly holds options for 9,897 shares.
Immunome, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. As of the April 16, 2026 record date, 113,249,519 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 Annual Meeting: James Boylan, Sandra Swain, M.D., and Philip Wagenheim. For example, Sandra Swain received 92,157,301 votes for and 224,265 votes withheld, with 11,768,578 broker non-votes.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 104,100,900 votes for, 27,134 against, and 22,110 abstentions. An advisory vote approved named executive officer compensation, with 90,908,436 votes for and 1,442,116 against. In a separate advisory vote on frequency, stockholders indicated a preference for annual say-on-pay votes, and the company will hold future advisory compensation votes every year in line with that preference.
Immunome Inc. director Jean Jacques Bienaimé reported offsetting trades in the company’s common stock on June 5, 2026. He made open-market purchases totaling 10,500 shares at prices between $19.27 and $19.48 per share and open-market sales totaling 10,500 shares at prices around $19.41–$19.44 per share, resulting in no net change in shares.
Following these transactions, he directly owned 42,915 shares of Immunome common stock. A footnote states that the sales were matchable with a 1,000‑share purchase under Section 16(b), and he agreed to pay $155 to Immunome, representing the full profit from that short-swing transaction.